Research & Development Articles
Three top vaccine producers are making newer vaccines that not only protect against the newer sublineages of COVID-19, but that also protect against other respiratory viruses.
Through regulatory pathways and patient engagement, FDA is helping to advance treatment innovations for rare diseases.
Does the shorter preparation time for fibrinogen concentrates make them a reasonable option in lieu of IFC in defined patient populations experiencing massive hemorrhage?
Specifically designed to blockade the physiologic IgG recycling function of endothelial cell neonatal crystallizable fragment receptor (FcRn), FcRn antagonists represent a new class of monoclonal antibody-based drugs that have been shown to mediate a sharp, dose-dependent reduction in circulation IgG levels.
With influenza apparently returning with a vengeance this season, the Centers for Disease Control and Prevention is once again alerting the public that vaccination is the most effective way to prevent infection from and to minimize risk of severe symptoms and hospitalization for serious flu-related complications.
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
Two recent studies effectively determined the antibody responses of pregnant women infected with SARS-CoV-2 and the effect of the fetal sex on those responses, as well as the direct clinical implications for COVID-19 infection and future maternal-fetal vaccination strategies.
New clinical studies show gene therapy may offer a cure for these chronic and expensive diseases in five to 10 years.
Virtual clinical trials may increasingly replace in-person trials due to their advantages in helping to bring drugs to market.
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
